cigna glp-1 coverage news today Weight loss drugs' high costs prompt to cut employee health plan Overview | Cigna Healthcare Newsroom

Emerging evidence suggests that GLP1 therapy can: Reduce hepatic fat content, as shown in MRI-PDFF studies Lower markers of liver inflammation and fibrosis Improve insulin sensitivity and metabolic control Although most trials focus on obese or diabetic populations, livercentric endpoints are increasingly evaluated, and benefits appear to extend beyond weight loss alone

Liraglutide, semaglutide and tirzepatide have been trialled for the management of obesity

As the informal economy dominates the worlds employment and the nature of urbanization, it also creates challenges, especially in developing countries, to comprehend and control informality

Regulatory classification shouldnt be interpreted as evidence of clinical safety or effectiveness